A
Power Law company profile
Adagene
Biotech & Life Sciences · Suzhou Shi, China · Founded 2012 · IPO 2021 Unicorn
Valuation
$168M
Market cap · Apr/2026
Revenue
$7.7M
Latest reported FY
Global footprint
Where Adagene has talent and traffic
AI talent share
1.2%
of workforce is AI talent
(1 of 83 staff)
(1 of 83 staff)
Core AI11.2%
Other AI00%
Non-AI workforce8298.8%
Web traffic by country
2.2K
monthly visits
across markets
across markets
🇺🇸 United States100%
Patent intelligence
$2M patent portfolio · 24 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$2M
1.2% of market cap · 168.9× smaller than top peer Genmab ($328M)
24 active patent families
Where Adagene innovates
Antiendomysial antibodiesCarcinosisMolecular biologyAnti antibodyCancer research
Below peer median on Legal, Market
Quality vs same-sector peers
Adagene on the five Patsnap quality dimensions
Adagene in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Adagene concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Adagene and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Adagene on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.